OncologyNovartis
Novartis Reports Phase 3 Results for Ofatumumab in Follicular Lymphoma
BMI
Biotechnology Media Insights
Editorial Team · August 25, 2025
Novartis announces Phase 3 trial results evaluating ofatumumab plus chemotherapy in patients with previously untreated advanced follicular lymphoma.
Novartis today announced Phase 3 trial results evaluating ofatumumab in combination with chemotherapy in patients with previously untreated advanced follicular lymphoma. The trial demonstrated significant improvements in progression-free survival compared to rituximab plus chemotherapy.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.